Safety and Preliminary Efficacy of L-arginine in Severe Falciparum Malaria

Menzies School of Health Research8 enrolled

Overview

Background: Mortality from severe malaria remains \~15% despite the use of the most rapidly parasiticidal antimalarial therapy, artesunate. Adjunctive treatments may improve outcome. Our overall goal is to determine if adjunctive treatment with L-arginine is safe and improves outcomes in severe malaria. In studies to date, we have shown that L-arginine is safe in moderately severe malaria, increases nitric oxide production and improves endothelial function. We now propose to extend these studies to patients with severe malaria. Aims: To determine the safety, preliminary efficacy, pharmacokinetics and pharmacodynamics of L-arginine infusion in severe malaria. Hypothesis: L-arginine will improve endothelial function, lactate clearance time and tissue oxygen delivery compared to saline with no clinically significant adverse effects. Methods: Based on previous pharmacokinetic modeling and simulations, we propose a phase 2A randomised controlled trial of L-arginine vs saline in severe malaria, each given over 8 hours. If safety is demonstrated this will be followed by a phase 2B open-label study of 24-hour infusion of L-arginine in severe malaria with safety and preliminary efficacy compared with the 8 hour infusions given in phase 2A. The primary outcomes will be the improvement in endothelial function and lactate clearance in patients given L-arginine infusion compared with those who received saline. Among the secondary outcomes will be safety and the effect of L-arginine vs saline on tissue oxygen delivery (NIRS). Data from both phase 2A and 2B will be used to generate a pharmacokinetic/ pharmacodynamic model.

See brief summary

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Enrollment

Interventions

L-arginine hydrochlorideDRUG

Patients will be randomized in two blocks of 18. The first block of 18 patients will receive either 12 g L-arginine or saline placebo. If safety is demonstrated in the first block, a further 18 patients will be enrolled in the second block and randomized to receive either 24g arginine or saline placebo Block 1: Standard RSMM artesunate regimen for severe falciparum malaria plus 12g of L-arginine diluted to a 10% solution and given over 8 hours (n=12); Block 2: Standard RSMM artesunate regimen for severe falciparum malaria plus a 24g dose of L-arginine diluted to a 10% solution given over 8 hours (n=12) Phase 2b: To evaluate any additional benefits of a longer infusion, a further 24 patients will receive L-arginine infusion 1.5g/hour for 24 hours

Normal salineOTHER

Patients with severe malaria will be randomized in two blocks of 18. The first block of 18 patients will receive either 12 g L-arginine or saline placebo. If safety is demonstrated in the first block, a further 18 patients will be enrolled in the second block and randomized to receive either 24g arginine or saline placebo. Blocks 1 and 2: Standard RSMM antimalarial artesunate regimen for severe falciparum malaria plus saline placebo, 240 ml given over 8 hours (n=12).

Eligibility

Sex: ALLMin age: 18 YearsMax age: 60 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. age 18-60 years 2. informed consent obtained 3. time of commencement of artesunate ≤18 hrs before infusion of L-arginine 4. any level of P. falciparum parasitemia, and one or more of the following criteria: i. acute renal failure (creatinine \>265umol/L) ii. hyperbilirubinemia (total bilirubin \>50 umol/L) with either renal impairment (creatinine \>130umol/L) or parasitemia of \>100,000 parasites/uL iii. blackwater fever iv. hyperparasitemia (\>10% parasitised red cells) v. cerebral malaria (Glasgow coma score \<11) vi. Hypoglycemia vii. Respiratory distress (RR \>32) Exclusion Criteria: 1. pregnancy or lactation 2. diabetes 3. serious pre-existing disease (cardiac, hepatic, kidney) 4. systolic blood pressure \<90 mmHg after fluid resuscitation 5. initial iSTAT test showing any of the following values: i. K+ \> 5.5 meq/L ii. Cl- \> 110 meq/L iii. HCO3- \< 15 meq/L 6. known allergy to L-arginine 7. evidence of concurrent bacterial infection 8. concurrent therapy with any of the following medications: iv. spironolactone, v. oral nitrates, vi. phosphodiesterase inhibitor (eg sildenafil \[Viagra\]) vii. alpha-blocking antihypertensive agents (eg prazosin) viii. L-arginine

Outcomes

Primary Outcomes

Improvement in endothelial function and lactate clearance.

Time frame: Endothelial function: end of 8 hour infusion. Lactate clearance: area under the curve until lactate returns to the upper limit of normal

Secondary Outcomes

Safety: Clinical and biochemical measures.

Time frame: During and after infusion. In those receiving L-arginine, biochemical and hemodynamic measures at the completion of infusion will also be compared with measures at the start of infusion.

Change in endothelial function in each arginine infusion regimen vs saline placebo combined

Time frame: 1 hour response and end of infusion response

Paired change in endothelial function

Time frame: paired comparison of post-vs pre-infusion values, overall, and in each arginine infusion regimen

Lactate clearance for each infusion regimen

Time frame: Time for lactate to return to upper limit of normal

Lactate:pyruvate ratio

Time frame: area under curve/time to normal

Fever clearance time

Time frame: Fever clearance time

parasite clearance time

Time frame: parasite clearance time

Change in L-arginine concentration

Time frame: at 1 and 8 hours

Improvement in microvascular obstruction (OPS)

Time frame: at 1 and 8 hours

Tissue oxygen consumption and delivery (NIRS)

Time frame: one and eight hours

change in exhaled NO

Time frame: one and eight hours

improvement in endothelial activation (decrease in angiopoietin-2 concentrations)

Time frame: area under curve

improvement in RHPAT among those with baseline dysfunction (RHPAT<1.67)

Time frame: 8 hours